---
schema_version: "secwatch.filing_event.v1"
accession: "0001728117-26-000073"
form_type: "8-K"
ticker: "GOSS"
cik: "0001728117"
company_name: "Gossamer Bio, Inc."
filed_at: "2026-08-13T20:02:19+00:00"
generated_at: "2026-08-13T20:03:15.122714+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Gossamer Q2 net income $16.9M; NDA on track Sept 2026; reacquires seralutinib rights

## Summary
- Q2 2026 net income $16.9M vs net loss $38.3M in Q2 2025; revenue $9.2M from Chiesi collaboration.
- NDA submission for seralutinib in PAH on track for Sept 2026; FDA feedback from Pre-NDA Type B meeting; potential approval decision Q3 2027.
- Reacquired worldwide rights to seralutinib from Chiesi; no upfront cash, Chiesi gets capped royalty and milestone payments.
- Exchanged $181.1M of 5.00% 2027 notes for $65.2M new 7.50% 2030 notes, reducing debt by ~$115.9M; 2027 notes now ~$18.9M.
- Cash $57.0M at June 30, 2026; expected to fund operations into Q1 2027.

## SEC filing metadata
- accession: 0001728117-26-000073
- form_type: 8-K
- ticker: GOSS
- cik: 0001728117
- company_name: Gossamer Bio, Inc.
- filed_at: 2026-08-13T20:02:19+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728117/000172811726000073/0001728117-26-000073-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728117/000172811726000073/goss-20260813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001728117-26-000073
- JSON: https://secwatch.observer/filing/0001728117-26-000073.json
- Plain text: https://secwatch.observer/filing/0001728117-26-000073.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.